Intravenous immunoglobulin for the treatment of acquired myasthenia gravis

Neurology

Volumn 51, Issue 6 SUPPL. 5, 1998, Pages

  Howard Jr , James F ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; CORTICOTROPIN; GAMMA INTERFERON; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; INTERLEUKIN 2;

ANTIBODY PRODUCTION; APHERESIS; ARTICLE; AUTOIMMUNE DISEASE; FATIGUE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MAINTENANCE THERAPY; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; PLASMAPHERESIS; PRIORITY JOURNAL; TREATMENT INDICATION;

EID: 0032421041     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.51.6_suppl_5.s30     Document Type: Article

References (73)

1. Conti-Fine BM, Protti MP, Bellone M, Howard JF. Myasthenia gravis: the immunobiology of an autoimmune disease. 1st ed. Austin, TX: RG Landes, 1997.
2. Lanska DJ. Indications for thymectomy in myasthenia gravis. Neurology 1990;40:1828-1829.
3. Protti MP, Manfredi AA, Wu XD, et al. Myasthenia gravis. CD4+ T epitopes on the embryonic gamma subunit of human muscle acetylcholine receptor. J Clin Invest 1992;90:1558-1567.
4. Sanders DB, Howard JF. Disorders of neuromuscular transmission. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, eds. Neurology in clinical practice. 2nd ed. Boston: Butterworth, 1995:1983-2002.
5. Tindall RSA, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987;316:719-724.
6. Niakan E, Harati Y, Rolak LA. Immunosuppressive drug therapy in myasthenia gravis. Arch Neurol 1986;43:155-156.
7. Howard JF. Treatment of myasthenia gravis with plasma exchange. Semin Neurol 1982;2:273-279.
8. Genkins G, Papatestas AE, Kornfeld P, Horowitz SH. Studies in myasthenia gravis: staging and gammaglobulin. In: Dau PC, ed. Plasmapheresis and the immunobiology of myasthenia gravis. Boston: Houghton-Mifflin, 1979;144-150.
9. Arsura EL, Bick A, Brunner NG, Namba T, Grob D. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 1986;146:1365-1368.
10. Besinger U, Fateh-Moghadam A, Knorr-Held S, et al. Immunomodulation in myasthenia gravis by high-dose intravenous 7-S immunoglobulins. Ann NY Acad Sci 1987;505:828-831.
11. Arsura E, Bick A, Brunner NG, Namba T, Grob D. High-dose immunoglobulin in the treatment of myasthenia gravis [Abstract]. Clin Res 1985;33:372A.
12. Cook D, Dalakas M, Galdi A, Biondi D, Porter H. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology 1990;40:212-214.
13. Cook L, Howard JF, Folds JD. Immediate effects of intravenous IgG administration on peripheral blood B and T cells and polymorphonuclear cells in patients with myasthenia gravis. J Clin Immunol 1988;8:23-31.
14. Cosi V, Lombardi M, Piccolo G, Erbetta A. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol Scand 1991;84:81-84.
15. Devathasan G, Kueh YK, Chong PN. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;2:809-810.
16. Edan G, Landgraf F. Experience with intravenous immunoglobulin in myasthenia gravis: a review. J Neurol Neurosurg Psychiatry 1994;57(Suppl):55-56.
17. Evoli A, Bartoccioni E, Palmisani MT, Provenzano C. IgG therapy in myasthenia gravis patients. J Autoimmun 1991; 4:R31.
18. Fateh-Moghadam A, Wick M, Besinger U, Geursen RG. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;1:848-849.
19. Gajdos PH, Outin H, Elkharrat D, et al. High-dose intravenous immunoglobulin for myasthenia gravis. Lancet 1984;1: 406-407.
20. Howard JF, Cook L, Folds JD. Intravenous gamma globulin for the treatment of myasthenia gravis: clinical, electrophysi-ological and immunological correlations [abstract]. Muscle Nerve 1986;9:155.
21. Ippoliti G, Cosi V, Piccolo G, Lombardi M, Mantegaz R. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;2:809.
22. Sakano T, Hamasaki T, Shimizu H, Harada Y, Ueda K. High-dose intravenous immunoglobulin for myasthenia gravis. Hiroshima J Med Sci 1988;37:7-9.
23. Ferrero B, Durelli L, Cavallo R, et al. Therapies for exacerbation of myasthenia gravis. The mechanism of action of intravenous high-dose immunoglobulin G. Ann NY Acad Sci 1993; 681:563-566.
24. Gajdos PH, Outin HD, Morel E, Raphaël JC, Goulon M. High-dose intravenous gamma globulin for myasthenia gravis: an alternative to plasma exchange? Ann NY Acad Sci 1987;505: 842-844.
25. Uchiyama M, Ichikawa Y, Takaya M, Moriuchi J, Scimizu H, Arimori S. High-dose gammaglobulin therapy of generalized myasthenia gravis. Ann NY Acad Sci 1987;505:868-871.
26. Vos JJE, van Aken WG, Engelfriet CP, von dem Borne AEGK. Intravenous gammaglobulin therapy in idiopathic thrombocytopenic purpura. Vox Sang 1985;49:92-100.
27. Furusho K. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984;2:1055-1058.
28. Evoli A, Palmisani MT, Bartoccioni E, Padua L, Tonali P. High-dose intravenous immunoglobulin in myasthenia gravis. Ital J Neurol Sci 1993;14:233-237.
29. Arsura EL, Bick A, Brunner NG, Grob D. Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci 1988;295:438-443.
30. Stricker RB, Kwiatkowska BJ, Habis JA, Kiprov DD. Myasthenic crisis: response to plasmapheresis following failure of intravenous gamma-globulin. Arch Neurol 1993;50:837-840.
31. Gajdos Ph, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997;41: 789-796.
32. Liblau R, Gajdos Ph, Bustarret FA, El Habib R, Bach JF, Morel E. Intravenous gamma-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies. J Clin Immunol 1991;11:128-131.
33. Dalakas MC. Experience with IVIg in the treatment of patients with myasthenia gravis. Neurology 1997;48:S64-69.
34. Zweiman B. Theoretical mechanisms by which immunoglobulin therapy might benefit myasthenia gravis. Clin Immunol Immunopathol 1989;53:S83-91.
35. Dietrich G, Algiman M, Sultan Y, Nydegger UE, Kazatchkine MD. Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg). Blood 1992;79:2946-2951.
36. Lefvert AK, Holm G, Pirskanen R. Autoantiidiotypic antibodies in myasthenia gravis. Ann NY Acad Sci 1987;505:133-154.
37. Dwyer D, Bradley RJ, Urquhart CK, et al. Naturally occurring anti-idiotypic antibodies in myasthenia gravis. Nature 1984;30:611-614.
38. Jungi TW, Nydegger UE. Proposed mechanisms of action of intravenous IgG (IVIG) in autoimmune diseases. Transfus Sci 1992;13:267-290.
39. Kurlander RJ. Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G. J Clin Invest 1980;66:773-781.
40. Atrah HI, Crawford RJ, Gabra GS, et al. Modulation of suppressor T-cells for the treatment of aplastic anaemia. Lancet 1985;2:339-340.
41. Templeton JG, Cocker JE, Crawford RJ, Forwell MA, Sandilands GP. Fcγ-receptor blocking antibodies in hyperimmune and normal pooled gammaglobulin. Lancet 1985;1:1337.
42. Koffman BM, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerve 1997;20:1102-1107.
43. Gidlund M, Orn A, Wigzell H, Senik A, Gressler I. Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature 1978;273:759-761.
44. Henney CS, Kuribayashi K, Kern DE, Gillis S. Interleukin 2 augments natural killer cell activity. Nature 1981;281:335-338.
45. Bussel JB, Lalezari P, Hilgartner MW, et al. Reversal of neutropenia with intravenous gammaglobulin in autoimmune neutropenia of infancy. Blood 1983;62:398-400.
46. Shinomiya N, Yata J. B and T cell involvement in antiacetylcholine receptor antibody formation in myasthenia gravis. Clin Exp Immunol 1981;46:277-285.
47. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor VIII by high-dose intravenous gammaglobulin. Lancet 1984;2:765-768.
48. Dalakas MC. Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects. Ann Neurol 1994;37:2-13.
49. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphlococcal toxin superantigens. J Clin Invest 1993;91: 602-607.
50. Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor endplate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlation. Mayo Clin Proc 1977;52:267-280.
51. Sahashi K, Engel AG, Lambert EH, Howard FM. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor endplate in myasthenia gravis. J Neuropathol Exp Neurol 1980;39:160-172.
52. Stangel M, Hartung HP, Marx P, Gold R. Intravenous immunoglobulin treatment of neurological autoimmune diseases. J Neurol Sci 1998;153:203-214.
53. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA. Recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA 1995;273: 1865-1870.
54. Kobosko J, Nicol P. Renal toxicity of intravenous immunoglobulin. Clin Nephrol 1992;37:216-217.
55. Phillips AO. Renal failure and intravenous immunoglobulin. Clin Nephrol 1992;37:216-217.
56. Ellie E, Combe C, Ferrer X. High-dose intravenous immune globulin and acute renal failure. N Engl J Med 1992;327: 1032-1033.
57. Schifferli JA, Lesley JF, Favre H, Imbach P, Nydegger U, Davies K High dose intravenous IgG treatment and renal function. Lancet 1991;337:457-458.
58. Steg RE, Lefkowitz DM. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology 1994;44:1180-1181.
59. Woodruff RK, Griff AP, Firkin FL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulins in elderly patients. Lancet 1986; 2:217-218.
60. Dodd LG, McBride JH. Transmission of hepatitis after the administration of intravenous immunoglobulins. Reply. Am J Clin Pathol 1993;99:649.
61. Lehner PJ, Webster ADB. Hepatitis C from immunoglobulin infusions. BMJ 1993;306:1541-1542.
62. Rousell RH, Dobkin MB, Budinger MD, Louie RE. Transmission of hepatitis after the administration of intravenous immunoglobulins. Am J Clin Pathol 1993;99:649.
63. Barton LL. Hepatitis C after immunoglobulin administration. Pediatr Infect Dis J 1996;15:558.
64. Jonas MM, Baron MJ, Bresee JS, Schneider LC. Clinical and virologic features of hepatitis C virus infection associated with intravenous immunoglobulin. Pediatrics 1996;98:211-215.
65. Yu MW. Follow-up studies of hepatitis C association with an intravenous immunoglobulin. Dev Biol Stand 1996;88:215-216.
66. Brox AG, Courogen PM, Sternbach M. Hemolytic anemia following intravenous gammaglobulin administration. Am J Med 1987;82:633-635.
67. Whittam LR, Hay RJ, Hughes RAC. Eczematous reactions to human immune globulin. Br J Dermatol 1997;137:481-482.
68. Harkness K, Howell SJ, Davies-Jones GAB. Encephalopathy associated with intravenous immunoglobulin treatment for Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1996;60:586.
69. Casteels-Van Daele M, Wijndaele L, Brock P, Kruger M, Gillis P. Aseptic meningitis associated with high dose intravenous immunoglobulin therapy. J Neurol Neurosurg Psychiatry 1992;55:980-981.
70. Ellis RJ, Swenson MR, Bajorek J. Aseptic meningitis as a complication of intravenous immunoglobulin therapy for myasthenia gravis. Muscle Nerve 1994;17:683-684.
71. Meiner Z, Ben-Hur T, River Y, Reches A. Aseptic meningitis as complication of intravenous immunoglobulin therapy fo r myasthenia gravis. J Neurol Neurosurg Psychiatry 1993;56: 830-833.
72. Van der Meché FGA, Kleyweg RP. Aseptic meningitis associated with high dose intravenous immunoglobulin therapy. J Neurol Neurosurg Psychiatry 1992;55:981.
73. Finkel AG, Howard JF, Mann JD. Successful treatment of headache related to intravenous immunoglobulin (IVIg) with antimigraine medications: a case report. Headache 1998;38: 317-321.